Refresh Checked Unchecked Menu Search Shopping bag Geolocation Person Facebook Instagram Twitter YouTube Info Icon CBC Icon CBC Shape CBD Icon CBD Shape CBG Icon CBG Shape THC Icon THC Shape THCV Icon THCV Shape
Advertise on Leafly

The FDA Is About to Deal With CBD—and Wants to Hear From You

April 3, 2019
Cannabidiol, or CBD, has become wildly popular in recent years—and widely available, both online and in stores across the country. But despite the belief by some that the 2018 farm bill broadly legalized the cannabinoid, the truth is that federal agencies are still scrambling to determine their next steps.

Want a say in the process? Now’s your chance.

The US Food and Drug Administration oversees the nation’s food, pharmaceutical drugs, and cosmetics—three categories of products that have recently been overwhelmed by CBD and various claims about its benefits. As the FDA begins to craft regulations around CBD and infused products, the agency is asking for public comment on how to proceed.

Related

Why CBD works better with a little THC (even if you don’t want to get high)

“While the use of cannabis and cannabis-derived products, including hemp and hemp-derived products, has increased dramatically in recent years, questions remain regarding the safety considerations raised by the widespread use of these products,” wrote Lowell Schiller, the FDA’s acting associate commissioner for policy, in a Federal Register filing published Tuesday. “These questions could impact the approaches we consider taking in regulating the development and marketing of products.”

Ahead of a public hearing on CBD scheduled for May 31 near Washington, DC, the agency is asking for public comment on three specific aspects of CBD and infused products: health and safety risks; manufacturing and product quality; and marketing, labeling, and sales.

Thoughts on CBD Regulation? File a Comment With the FDA

More information is available on the federal government’s Regulations.gov website (click here to go directly to the comment form). Written comments can be sent to:

Dockets Management Staff (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

Related

How to find the best CBD cannabis product for you

Requests to speak or make a presentation at the May 31 hearing must be received by May 10, while written or electronically filed comments can be filed until much later: July 2.

Outlook: Uncertain

It’s hard to gauge how the FDA might proceed with regulating CBD. On one hand, the agency has been far more responsive to scientific evidence around cannabinoids than the US Drug Enforcement Administration. Late last year, FDA officials wrote to their counterparts at the DEA explaining that “CBD and its salts … do not have a significant potential for abuse and could be removed from the [Controlled Substances Act].” Meanwhile, the DEA has repeatedly insisted that any CBD product other than the pharmaceutical drug Epidiolex remains a Schedule I controlled substance.

Related

US Reschedules CBD Drug—but Not CBD Itself

But while the FDA seems more sympathetic to CBD, the agency is also trying to rein in an industry that has exploded in recent years. Hundreds of startups have exploited the legal uncertainty around CBD by insisting that cannabidiol products are already “legal in all 50 states” and promising relief for all types of ailments, whether backed by evidence or not.

“There’s too much money to be made for problems not to come up.”
Justin Polkis, Virginia Commonwealth University

That does not sit well with FDA officials. Earlier this week they took action, sending warning letters to three CBD companies—Nutra Pure, PotNetwork Holdings, and Advanced Spine and Pain—that agency officials say were making false claims about the use of CBD to treat diseases such as cancer and Alzheimer’s disease.

“According to their advertisements, the products can effectively treat diseases, including cancer, Alzheimer’s disease, fibromyalgia, and ‘neuropsychiatric disorders,’” the FDA and FTC said in a joint statement.

“We’ve seen, or heard of interest in, products containing cannabis or cannabis derivatives that are marketed as human drugs, dietary supplements, conventional foods, animal foods and drugs, and cosmetics, among other things,” FDA Commissioner Dr. Scott Gottlieb said in the statement. (Gottlieb, who has pressed his agency to take action on CBD, is scheduled to step down from his post later this month.)

After last year’s passage of the farm bill, the FDA issued a statement saying that CBD in food products is prohibited under the federal Food, Drug, and Cosmetic Act. As a result, national drug store chains such as CVS have begun to carry CBD products, but only in non-edible form.

Related

CVS Ignores DEA, Says It’s Already Selling CBD Products

In the Federal Register post about the upcoming hearing, the FDA also raised concerns about the possibility of liver damage as the result of taking high doses of CBD (20 millilgrams of CBD per kilogram of body weight per day, or about 1,360 mg for a 150-lb. person). It says the risk was determined as part of the FDA approval process for Epidiolex, a purified form of CBD approved last year to treat certain forms of epilepsy.

“This is a potentially serious risk that can be managed when the product is taken under medical supervision in accordance with the FDA approved labeling for the product, but it is less clear how this risk might be managed if this substance is used far more widely, without medical supervision, and not in accordance with FDA-approved labeling,” the Federal Register filing says.

For reference, acetaminophen—a popular pain reliever and fever reducer found in over-the-counter drugs such as Tylenol and Nyquil—is a leading cause of acute liver failure across much of the globe. “Harmless at low doses, acetaminophen has direct hepatotoxic potential when taken as an overdose and can cause acute liver injury and death from acute liver failure,” according to the National Institutes of Health.

Related

Tests of CBD oils reveal three surprise chemicals, one big problem

The current unregulated nature of CBD has also raised concerns among consumers and outside observers for other reasons. Among them, a study last year by researchers at Virginia Commonwealth University (VCU) found unlabeled contaminants in a number of products sold by Diamond CBD, a retailer owned by PotNetwork Holdings. The unexpected chemicals included dextromethorphan (DXM)—a well-known cough medicine with a history of recreational abuse and health dangers—and 5F-ADB, one of a growing group of synthetic cannabinoids often known as K2 or Spice.

“Somebody needs to step in and regulate this stuff,” Justin Polkis, the lead author of the VCU study told Leafly last year. “There’s too much money to be made for problems not to come up.”

Diamond CEO Kevin Hagen told Leafly at the time that he welcomed regulation.

“All companies make big claims about their products,” Hagen said. “It’s the FDA’s job to ask for [better] labeling.”

Ben Adlin's Bio Image

Ben Adlin

Ben Adlin is a senior editor at Leafly who specializes in politics and the law. Follow him on Twitter: @badlin

View Ben Adlin's articles

  • Ole Sørensen

    Regulation and clarity much needed. And CBD must of course be legal.

  • familyguy

    Well I hope the FDA intentions are good but most of the time they are involved, it is a major setback. Setbacks in the cannabis industries have occurred since the Trump administration took office this is another issue people must note.

    • ohhhdear

      What setbacks has Trump caused?

      • Brad

        He’s embarrassed us to the whole world.

        • ohhhdear

          That was your opinion of Trump. That wasn’t my question.

        • Dana Chisholm Tindell

          Oh, Bull

    • Patriot9/11

      AMEN. They get in on things and all the unintended consequences of their actions roll out en mass. Why would they treat CBD any different than any of the other “natural” products on the market? Answer: head in sand attitude over cannabis, CBD, THC or anything that sounds or smells like it. The leaders of this country blew it 10 years ago when the handwriting was on the wall about cannabis. Instead of acting, they “kicked it down the road”, something they are good at. The FDA and DEA are complicit in this also. The states, meanwhile, have gone off “willy-nilly” with their regulations, none of which are the same. Now, in an effort to make up for their mistake, I fear the FDA and DEA will over-react and make this amazing substance hard to acquire for those that find it a miracle. This too would be a typical government action in such a case. Whatever is done about CBD needs to be focused on quality and contamination … that the bottle contains CBD in the quantity it states and there’s no junk in it. If they go any further, we can depend on absurd and restrictive laws that do no one any good.

  • Tony Berkopes

    If the FDA outlaws CBD the only reason is because big pharma has paid them off. PERIOD!

  • The mad yooper

    The natural products question is a trap.
    For instance: tobacco, has to have a safety label on it warning of it’s health risks. Otherwise the tobacco companies could be advertising its health benefits real or imaginary. We can grow this in our garden.
    Corn and most grains. We can grow this in our garden and do pretty much what we want with it. Provided that when we distill it we follow the rules and don’t make more than the law allows and sell it.
    Granted both of these instances fall under the ATF. It makes little difference which alphabet agency ends up being the road block.
    What we currently have has a wild west feel to it.
    We have the opportunity to make our case. Some of us will resent any type of consumer protection while others will demand the strict regulation and enforcement of regulation.
    The truth is always in the middle. Hopefully the regulation is too.

  • Butch Native420

    The FDA sucks and has been paid off not to legalize CBD and everyone knows it!!! They will waste everyones time and money and won’t do a damn thing to legalize anything but what their rich masters big pharma want them to legalize. Big pharma has it’s own plans with CBD and then the FDA will approve it. Just wait and see. Hope I am proven wrong but I doubt it.

  • horsemannv

    Fully LEGALIZE and Full DECRIMINALIZE all Cannabis that is on schedule. Treat it like alcohol. Establish when and where it can be used. Keep grow rules or expand them. It has already been established that Cannabis is much less harmful to a person than Alcohol and has far fewer negative social ramifications than Alcohol. If I can make bathtub Gin then I should be able to grow my own Cannabis. If I can buy a craft beer production set-up at a store then I should be able to grow my own cannabis. It is the government that has screwed up cannabis cultivation and hemp cultivation historically, just like they screw up everything else. Remember the “LOTTO” craze? Where did that tax money go? It was supposed to go to strictly for education. Instead it when to exclusive Charter Schools and other government expense /privatization programs. The same thing is happening with Cannabis. Devote all cannabis tax to education. Period. Do NOT use it to fund corporate welfare/socialism or privatization of public services!! This is your government…Stand Up and be counted. Get involved in your and your kids lives.